title: [Endometrial cancers arising in polyps associated with tamoxifen use].
abstract: OBJECTIVE
  To review and describe the anatomoclinical cases of the endometrial cancers arising on polyps during a hormonotherapy by tamoxifen for breast cancer.
  
  
  METHODS
  In the surgical inventory 1990-2002 of the benign or malignant uterine lesions investigated by hysteroscopy with dilatation & curettage (D&C) and/or hysterectomy, 108 single or multiple endometrial polyps were encountered and histologically analyzed.
  
  
  RESULTS
  A malignant transformation of polyp was found in 5 instances, meaning a rate of 4.6% i.e. 5/108: 4 cases of adenocarcinoma, 1 case of sarcoma.
  
  
  CONCLUSIONS
  The existence of endometrial polyps - symptomatic or not - does not seem compatible with the prolonged use of tamoxifen treatment owing the estrogen agonist potential effects of tamoxifen and its well-known hyperplastic and carcinogenic properties for the endometrium. The increased risk of endometrial cancer developing in polyps in this iatrogenic context is estimated between 2.5% and 10% in the literature.
authors.affiliation: Service de chirurgie, centre de lutte contre le cancer (CLCC) Jean-Perrin, Clermont-Ferrand, France.
authors.forename: B Anama
authors.initials: BA
authors.lastname: Mbatsogo
authors.forename: G
authors.initials: G
authors.lastname: Le Bouëdec
authors.forename: T
authors.initials: T
authors.lastname: Michy
authors.forename: N
authors.initials: N
authors.lastname: Bourdel
authors.forename: G
authors.initials: G
authors.lastname: Fouilloux
authors.forename: J
authors.initials: J
authors.lastname: Dauplat
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects* / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy; D002471:Cell Transformation, Neoplastic / Q000139:chemically induced*; D016889:Endometrial Neoplasms / Q000139:chemically induced* / Q000453:epidemiology; D005260:Female; D006801:Humans; D008875:Middle Aged; D011127:Polyps / Q000473:pathology*; D012307:Risk Factors; D013629:Tamoxifen / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D018931:Antineoplastic Agents, Hormonal; D013629:Tamoxifen